{"id":1774,"date":"2002-04-01T12:08:00","date_gmt":"2002-04-01T10:08:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/die-kombination-von-azetylsalizylsaeure-und-antikoagulanzien-nach-myokardinfarkt-ist-ohne-zusaetzlichen-nutzen-die-champ-studie"},"modified":"2002-04-01T12:08:00","modified_gmt":"2002-04-01T10:08:00","slug":"die-kombination-von-azetylsalizylsaeure-und-antikoagulanzien-nach-myokardinfarkt-ist-ohne-zusaetzlichen-nutzen-die-champ-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/die-kombination-von-azetylsalizylsaeure-und-antikoagulanzien-nach-myokardinfarkt-ist-ohne-zusaetzlichen-nutzen-die-champ-studie","title":{"rendered":"Die Kombination von Azetylsalizyls\u00e4ure und Antikoagulanzien nach Myokardinfarkt ist ohne zus\u00e4tzlichen Nutzen. Die CHAMP-Studie"},"content":{"rendered":"<p>In den Jahren 1992-97 wurden an 78 Veterans Affairs Medical Centers in den USA \u00fcber 20000 Patienten mit akutem Myokardinfarkt behandelt. Ein Viertel dieser Patienten (n = 5059) wurden in die CHAMP-Studie (Combination Hemotherapy And Mortality Prevention; Fiore, L.D., et al.: Circulation 2002, 105, 557) eingeschlossen. Sie erhielten innerhalb von 14 Tagen nach dem Infarkt [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In den Jahren 1992-97 wurden an 78 Veterans Affairs Medical Centers in den USA \u00fcber 20000 Patienten mit akutem Myokardinfarkt behandelt. Ein Viertel dieser Patienten (n = 5059) wurden in die CHAMP-Studie (Combination Hemotherapy And Mortality Prevention; Fiore, L.D., et al.: Circulation 2002, 105, 557) eingeschlossen. Sie erhielten innerhalb von 14 Tagen nach dem Infarkt [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[74,77,76,3955,71,65,138,136],"class_list":["post-1774","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-acetylsalicylsaeure","tag-ass","tag-azetylsalizylsaeure","tag-champ-studie","tag-herzinfarkt","tag-myokardinfarkt","tag-phenprocoumon","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1774","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1774"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1774\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1774"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1774"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1774"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}